Price Crosses Moving Average
|Bid||13.94 x 1000|
|Ask||15.35 x 1100|
|Day's Range||14.34 - 15.29|
|52 Week Range||10.19 - 20.95|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merus N.V. (NASDAQ:MRUS) shareholders should be happy to see the share price up 21% in the last month. But that cannot...
Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (NASDAQ:MRUS) came out with its annual results last week, and we wanted to see how the business is...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Merus N.V. (NASDAQ:MRUS) last week reported its latest quarterly results, which makes it a good time for investors to...
Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Merus N.V. (NASDAQ:MRUS). Is Merus N.V. (NASDAQ:MRUS) a buy right […]
Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
The big shareholder groups in Merus N.V. (NASDAQ:MRUS) have power over the company. Institutions often own shares in...
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.